American Century Companies Inc. Has $21.04 Million Stake in Teva Pharmaceutical Industries Ltd (TEVA)

American Century Companies Inc. lowered its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 30.9% in the 4th quarter, Holdings Channel reports. The fund owned 1,110,041 shares of the company’s stock after selling 495,886 shares during the period. American Century Companies Inc.’s holdings in Teva Pharmaceutical Industries were worth $21,035,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Exane Derivatives bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $571,000. Korea Investment CORP raised its stake in shares of Teva Pharmaceutical Industries by 14.3% during the third quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock valued at $4,308,000 after acquiring an additional 30,674 shares during the last quarter. Private Capital Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 51.3% during the third quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock valued at $459,000 after acquiring an additional 8,850 shares during the last quarter. Financial Counselors Inc. raised its stake in shares of Teva Pharmaceutical Industries by 28.8% during the third quarter. Financial Counselors Inc. now owns 181,130 shares of the company’s stock valued at $3,188,000 after acquiring an additional 40,531 shares during the last quarter. Finally, Lockheed Martin Investment Management Co. bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at $317,000. 51.93% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently weighed in on TEVA shares. Credit Suisse Group set a $20.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Monday, January 22nd. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 8th. Cantor Fitzgerald set a $10.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Monday, November 27th. Royal Bank of Canada raised shares of Teva Pharmaceutical Industries from an “underperform” rating to a “sector perform” rating and set a $18.00 target price for the company in a research note on Friday, February 9th. Finally, Vetr downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 target price for the company. in a research note on Thursday, January 11th. Ten investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $21.26.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) opened at $19.33 on Thursday. The firm has a market cap of $19,890.00, a price-to-earnings ratio of -1.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.59. Teva Pharmaceutical Industries Ltd has a 52 week low of $10.85 and a 52 week high of $37.94. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. The firm had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 14.52%. The business’s revenue was down 15.9% on a year-over-year basis. During the same period last year, the company earned $1.38 earnings per share. equities research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.69 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “American Century Companies Inc. Has $21.04 Million Stake in Teva Pharmaceutical Industries Ltd (TEVA)” was originally reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.themarketsdaily.com/2018/02/15/american-century-companies-inc-has-21-04-million-stake-in-teva-pharmaceutical-industries-ltd-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply